Temasek Holdings Private Ltd Reduces Position in Guardant Health, Inc. (NASDAQ:GH)

Temasek Holdings Private Ltd reduced its position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 25.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,561,979 shares of the company's stock after selling 526,215 shares during the quarter. Temasek Holdings Private Ltd owned approximately 1.26% of Guardant Health worth $47,718,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Guardant Health during the fourth quarter valued at about $26,000. SBI Securities Co. Ltd. bought a new position in Guardant Health during the 4th quarter valued at approximately $43,000. Kimelman & Baird LLC purchased a new stake in Guardant Health in the 4th quarter worth approximately $58,000. NewEdge Advisors LLC lifted its holdings in Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after buying an additional 230 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $61,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

Insider Activity

In related news, CEO Amirali Talasaz sold 106,784 shares of Guardant Health stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the sale, the chief executive officer now owns 2,202,672 shares of the company's stock, valued at $107,952,954.72. The trade was a 4.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 107,132 shares of company stock valued at $5,248,393 over the last three months. Insiders own 6.10% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. JPMorgan Chase & Co. upped their target price on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a report on Friday, February 21st. The Goldman Sachs Group raised their target price on shares of Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. UBS Group boosted their price target on shares of Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Mizuho initiated coverage on shares of Guardant Health in a research note on Thursday, April 10th. They issued an "outperform" rating and a $55.00 price target for the company. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Guardant Health in a research report on Monday, May 5th. Twenty-one investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Guardant Health presently has a consensus rating of "Buy" and an average target price of $52.32.

Guardant Health Trading Up 2.3%

GH stock traded up $0.84 during midday trading on Friday, hitting $37.89. The company's stock had a trading volume of 496,047 shares, compared to its average volume of 2,157,196. The company has a market cap of $4.69 billion, a PE ratio of -10.63 and a beta of 1.49. The firm's 50-day moving average is $43.50 and its 200-day moving average is $39.96. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The company had revenue of $203.47 million for the quarter, compared to analysts' expectations of $189.91 million. During the same period last year, the firm posted ($0.46) earnings per share. Guardant Health's revenue was up 20.8% compared to the same quarter last year. Analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.